Trovagene (TROV) Misses Q2 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Trovagene, Inc. Announces Second Quarter 2015 Financial Results
August 10, 2015 4:05 PM EDTSAN DIEGO, Aug. 10, 2015 /PRNewswire/ --Â Trovagene, Inc. (NASDAQ:Â TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the three months and six months ended June 30, 2015.
"Our pilot commercial team has gained impressive traction in the field, delivering stronger than expected participation by oncologists in our Clinical Experience Program," said Antonius Schuh, Ph.D., chief executive officer of Trovagene. "Additionally, we continue to demonstrate in clinical studies the utility of our Precision Cancer Monitoring platform to detect and monitor... More
